Abivax shares among the steepest declines on the SBF 120, under pressure despite its results
Following the presentation of its half-year results on September 21, the Paris-based biotech company continues its decline this Tuesday, in a market that is nevertheless well-oriented. The stock stands out in contrast to a slightly positive SBF 120, intensifying pressure that has been building for several weeks.
Abivax among the steepest declines on the SBF 120, in sharp contrast with the index
Abivax is down 2.21% to €88.65 during the session, while the SBF 120 is up 0.32% in the same timeframe. The stock thus finds itself among the steepest declines on the SBF 120, in a context of a globally supportive European market, with the CAC 40 advancing 0.31% and the DAX 0.94%. This divergence reflects a underlying trend: the stock has lost nearly 11% over the week and nearly 13% over the month, widening the gap from its early summer levels, even though the one-year performance remains positive at over 26%. The three moving averages are weighing on the technical setup.
The price is below the 20-day MA (€97.47, representing a -9.05% gap), below the 50-day MA (€105.47, a -15.95% gap) and below the 200-day MA (€102.73, a -13.71% gap). The RSI at 33 reflects persistent selling pressure, without having reached extreme oversold levels. The stock is also trading below its support threshold at €90.45, a level it had broken through to the downside in recent days, and remains far from the resistance at €111.10.
Short sellers still well-positioned despite a reduction in their positions
Net short positions declared on Abivax remain elevated, despite a notable decline over one month: five funds cumulate 5.74% of capital positioned downward (latest declaration on September 16), compared to 7.05% thirty days ago, representing a reduction of 1.31 percentage points. This level remains significant for a company of this size, reflecting that a substantial portion of institutional investors maintains a bearish bet on the biotech, even if the recent reduction marks a form of partial covering following the stock decline. Two dynamics are thus intersecting: shorts that are gradually reducing, and a stock that continues to slide. The first half 2026 accounts, presented on September 21, show a widened net loss and increased R&D spending, as part of preparations for the regulatory filing of obefazimod expected by year-end.
The company provides financial visibility through the fourth quarter of 2029. The next tangible signal for the stock remains this regulatory filing, with a deadline set for end of 2026.
